Novo inks $1.4B pact with Orbis to push oral macrocycle therapies
TL;DR Summary
Novo, which recently rebranded from Novo Nordisk, struck a potential $1.4 billion biobucks deal with Orbis Medicines to develop orally bioavailable macrocycle therapies for cardiometabolic diseases, leveraging Orbis's AI-enabled nGen platform. The agreement includes upfront and milestone payments plus a strategic investment and marks Orbis’s first Big Pharma pact, with exact targets not disclosed.
- Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech Fierce Biotech
- Novo, Orbis sign up to $1.4 billion deal to develop oral drugs reuters.com
- Novo Nordisk Signs Up To $1.4 Billion Licensing Deal With Orbis Medicines Yahoo Finance
- Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo Endpoints News
- Novo Nordisk Signs Agreement With Orbis Medicines to Develop Therapeutics for Cardiometabolic Diseases marketscreener.com
Reading Insights
Total Reads
1
Unique Readers
6
Time Saved
2 min
vs 3 min read
Condensed
89%
488 → 54 words
Want the full story? Read the original article
Read on Fierce Biotech